Track topics on Twitter Track topics that are important to you
ATLANTA — In this video exclusive, E. Michael Lewiecki, MD, FACP, FACE, director of New Mexico Clinical Research and Osteoporosis Center in Albuquerque, discusses the new osteoporosis drug abaloparatide, a synthetic form of human parathyroid hormone-related protein, designed to stimulate bone formation without also stimulating as much bone resorption as other agents.Lewiecki reports that the number needed to treat to prevent one vertebral fracture with abaloparatide over 18 months is 28, which is a bit lower than the number needed to treat with teriparatide. In a higher-risk population, similar to that in the Fracture Intervention Trial of alendronate, the number needed to treat is 8, according to Lewiecki’s data.NEXT ARTICLE
Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...